KaratAB, JeevaratnamA, KaratS, RaoPS. Double-blind controlled clinical trial of clofazimine in reactive phases of lepromatous leprosy. Br Med J., 1970; 1:198–200.
2.
TangS, YaoL, HaoX, et al.Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis., 2015; 60:1361–1367.
3.
BelleraCL, BalcazarDE, VanrellMC, et al.Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir. Eur J Med Chem., 2015; 93:338–348.
4.
LoughlinEH, RiceJB, WellsHS, RappaportI, JosephAA. The treatment of Plasmodium falciparum malaria with a single dose antimalarial; a preliminary report of the use of hydroxychloroquine, 7-chloro-4(4-(N-ethyl-N-B-hydroxyethylamino)-1-methylbutylamino)-quinoline diphosphate. Antibiot Chemother (Northfield), 1952; 2:171–174.
5.
BrodthagenH. Hydroxychloroquine (plaquenil) in the treatment of lupus erythematosus. Acta Derm Venereol., 1959; 39:233–237.
6.
Comín-ColetJ, Sánchez-CorralMA, Alegre-SanchoJJ, et al.Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus, 2001; 10:59–62.
7.
JoyceE, FabreA, MahonN. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care, 2013; 2:77–83.
8.
OlsenNJ, SchleichMA, KarpDR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum., 2013; 43:264–272.
9.
AmsterdamJD, BrunswickDJ, HundertM. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A—a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry, 2002; 26:1333–1338.
10.
AndrikopoulosGK, PastromasS, TzeisS. Flecainide: current status and perspectives in arrhythmia management. World J Cardiol., 2015; 7:76–85.
11.
VeeraraghavanR, LinJ, HoekerGS, KeenerJP, GourdieRG, PoelzingS. Sodium channels in the Cx43 gap junction perinexus may constitute a cardiac ephapse: an experimental and modeling study. Pflugers Arch.Jan13, 2015. [Epub ahead of print]
12.
KuriyamaK. Ethanol-induced changes in activities of adenylate cyclase, guanylate cyclase and cyclic adenosine 3′,5′-monophosphate dependent protein kinase in the brain and liver. Drug Alcohol Depend., 1977; 2:335–348.
13.
BellRL, LopezMF, CuiC, et al.Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol., 2015; 20:38–42.
14.
FinkelsteinM, KromerCM, SweeneySA, DelahuntCS. Some aspects of the pharmacology of clemizole hydrochloride. J Am Pharm Assoc Am Pharm Assoc., 1960; 49:18–22.
15.
EinavS, SobolHD, GehrigE, GlennJS. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J. Infect Dis., 2010; 202:65–74.
16.
BarabanSC, DindayMT, HortopanGA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun., 2013; 4:2410.
17.
WinterMJ, RedfernWS, HayfieldAJ, OwenSF, ValentinJP, HutchinsonTH. Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs. J Pharmacol Toxicol Methods, 2008; 57:176–187.
18.
BauerDE, KamranSC, OrkinSH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood, 2012; 120:2945–2953.
19.
CharacheS, DoverGJ, MoyerMA, MooreJW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood, 1987; 69:109–116.
20.
WittO, MonkemeyerS, RönndahlG, et al.Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood, 2003; 101:2001–2007.
21.
IqbalS, BazianyA, HussainM, et al.Trimetazidine as a potential neuroprotectant in transient global ischemia in gerbils: a behavioral and histological study. Brain Res., 2002; 928:1–7.
22.
LogigianEL, MartensWB, MoxleyRT4th, et al.Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology, 2010; 74:1441–1448.
23.
RomeroMR, EfferthT, SerranoMA, et al.Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an “in vitro” replicative system. Antiviral Res., 2005; 68:75–83.
24.
EfferthT, RomeroMR, WolfDG, StammingerT, MarinJJ, MarschallM. The antiviral activities of artemisinin and artesunate. Clin Infect Dis., 2008; 47:804–811.
25.
HayashiK, MinodaK, NagaokaY, HayashiT, UesatoS. Antiviral activity of berberine and related compounds against human cytomegalovirus. Bioorg Med Chem Lett., 2007; 17:1562–1564.
